摘要 目的观察老年HER2阴性晚期乳腺癌患者应用氟维司群联合瑞博西林的治疗效果。方法选取在武汉市中心医院新洲院区2017年6月-2019年6月期间进行内分泌治疗的乳腺癌晚期患者150例,依据随机数字表法分为观察组和对照组,每组75例。对照组予以氟维司群治疗,观察组予以氟维司群联合瑞博西林治疗。疗程结束后,评估并比较2组治疗效果、用药安全性和随访情况。结果治疗后,观察组临床获益率(CBR)和客观缓解率(ORR)明显高于对照组(P<0.05);2组患者不良反应在乏力、关节痛、潮热、肢体麻木、胃肠道反应和肝功能损害方面差异无统计学意义(P>0.05);观察组不良反应在中性粒细胞减少和白细胞减少方面的发生率明显高于对照组;对照组无进展生存期(PFS)(24.74±3.43个月)和总生存期(OS)(35.87±5.26个月)明显长于对照组的PFS(17.19±2.62个月)和OS(25.28±4.29个月)(P<0.05)。结论老年HER2阴性晚期乳腺癌患者采用氟维司群联合瑞博西林治疗,可有效提高临床获益率和客观缓解率,显著延长无进展生存期和总生存期,安全性较好。 Objective To observe the therapeutic effect of fulvestrant combined with reboxillin in elderly patients with human epidermal growth factor receptor 2(HER2)-negative advanced breast cancer.Methods 150 patients with HER2-negative advanced breast cancer who received endocrine therapy in Xinzhou Branch of Central Hospital of Wuhan City from June 2017 to June 2019 were selected and divided randomly into observation group and control group,75 cases in each group.The control group was treated with fulvestrant,and the observation group was treated with fulvestrant combined with reboxillin.After the treatment,the therapeutic effect,medication safety and follow-up situation were evaluated and compared between the two groups.Results After treatment,the clinical benefit rate (CBR)and objective response rate(ORR)of the observation group were significantly higher than those of the control group(P<0.05).There was no significant difference in the adverse reactions between the two groups in fatigue,joint pain,hot tide,numbness of limbs,gastrointestinal reaction and liver function damage(P>0.05),and the incidence of adverse reactions of neutropenia and leucopenia in the observation group was significantly higher than that in the control group,but the progression-free survival(PFS)(24.74±3.43 months)and overall survival(OS)(35.87±5.26 months)of the observation group were significantly longer than those of the control group[PFS(17.19±2.62)months and OS(25.28±4.29)months](P<0.05).Conclusion The treatment of elderly patients with HER2-negative advanced breast cancer with fulvestrant combined with reboxillin can effectively improve the clinical benefit rate and objective remission rate,significantly prolong PFS and OS,and its safety is good.
机构地区 武汉市中心医院新洲院区（武汉市新洲区人民医院）胸外肿瘤外科 武汉市中心医院新洲院区（武汉市新洲区人民医院）感染科 武汉市中心医院新洲院区（武汉市新洲区人民医院）妇科 上海交通大学医学院附属仁济医院妇科
出处 《老年医学与保健》 CAS 2021年第2期241-244,共4页 Geriatrics & Health Care
关键词 老年 HER2阴性 晚期乳腺癌 氟维司群 瑞博西林 临床疗效 elderly HER2-negative advanced breast cancer fulvestrant reboxillin clinical efficacy
分类号 R73 [医药卫生—肿瘤]
